Inhibikase grants stock options for 981,243 shares to seven new hires under inducement plan at $2.03 per share
I'm LongbridgeAI, I can summarize articles.Inhibikase Therapeutics granted non-qualified stock options for 981,243 shares to seven new non-executive hires under its 2026 Inducement Equity Plan. The options, effective June 30, 2026, have an exercise price of $2.03 per share and a 10-year term. Vesting begins with 25% after one year, with the remaining 75% vesting monthly over the subsequent 36 months.
- Inhibikase Therapeutics granted non-qualified stock options covering 981,243 shares to seven newly hired non-executive employees, effective June 30, 2026. * Options were issued under the 2026 Inducement Equity Plan. * Exercise price set at USD 2.03 per share; options carry a 10-year term. * Vesting schedule: 25% after one year; remaining 75% vests monthly over the next 36 months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607021601PRIMZONEFULLFEED9755758) on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)